Agenda
Cancer Progress 2010
March 16-17, 2010
The Hilton New York - Trianon Ballroom

Tuesday, March 16

7:00 – 8:00 am    Registration, Continental Breakfast  

8:00 – 8:30          Welcome, Introductory Remarks, Conference Overview
                             Jeremy P. Goldberg, JPG Healthcare LLC, Tuesday Moderator

 8:30 - 10:30        Panel Discussion: Steps on the Promise of Targeted Therapies
                            Markus Goebel, MD, PhD, Managing Director, Novartis Venture Fund
                            Prof. Michel Aguet, MD, Director, Swiss Institute for Experimental Cancer Research (ISREC)
                            Neal Rosen, MD, PhD, Enid A. Haupt Chair in Medical Oncology, Memorial Sloan-Kettering Cancer Center
                            Christian Rommel, PhD, CSO, Intellikine
                            Albert S. Yu, MD, VP, Clinical Affairs & CMO, Calistoga Pharmaceuticals
                            Li Yan, MD, PhD, Director, Clinical Oncology, Merck
                            Barry Childs, MD, Associate Vice President, Oncology Medical Affairs, sanofi aventis US
                            Robert Copeland, PhD, EVP & CSO, Epizyme
                            K. Peter Hirth, PhD, CEO, Plexxikon
                            Martine George, MD, MSc, VP, Medical Affairs, Pfizer Oncology

10:30 – 11:00      Networking Break

11:00 – 11:45      Keynote Address: Cancer Stem Cells and the Development of High-Grade Malignancy
                             Robert Weinberg, PhD, Member, Whitehead Institute, Professor of Biology, MIT

11:45 - 12:45       Panel Discussion: Genomic Strategies for Rational Combinations of Targeted Therapies
                             David C. Heimbrook, PhD, VP Oncology Global Therapeutic Area, Roche
                             David Solit, MD, Elizabeth and Felix Rohatyn Chair, Memorial Sloan-Kettering Cancer Center
                             Jeffrey Engelman MD, PhD, Assistant Professor in Medicine, Harvard Medical School, Director, Thoracic Oncology, Mass General Hospital Cancer Center
                             Brian Leyland-Jones, MD, PhD, Winship Cancer Institute, Emory University
                             Colin Hill, CEO, Gene Network Sciences
                             Stuart Lutzker, MD, PhD, VP BioOncology Exploratory Clinical Development, Genentech

  12:45 – 2:00 pm         Luncheon

2:00 – 3:00           Panel Discussion: Patient Stratification: Impact on Drug Development and Commercialization
                              Richard Gaynor, MD, VP, Cancer Research & Clinical Investigation, Eli Lilly
                              Joseph R. Nevins, PhD, Barbara Levine Professor for Breast Cancer, Director, IGSP Center for Applied Genomics and Technology, Duke University Med Ctr
                              David Schenkein, MD, PhD, CEO, Agios Pharmaceuticals
                              Steven J. Heller, Global Marketing Leader, Oncology GSM, Worldwide Strategic Marketing, Johnson & Johnson  
                              Matthew Meyerson, MD, PhD, Professor of Pathology, Harvard Medical School/Broad Institute

 3:00 – 3:30           Networking Break

3:30 – 5:30           Panel Discussion: Do Novel Therapeutics Need Companion Diagnostics?
                              Steven D. Averbuch, MD, VP Oncology Transition Strategy & Development and Head, Pharmacodiagnostics Global Clinical Research, Bristol-Myers Squibb
                              Brian Leyland-Jones, MD, PhD, Winship Cancer Institute, Emory University
                              Daniel J. Sargent, PhD, Professor of Oncology, Professor of Biostatistics, Mayo Clinic
                              Neil Gunn, MSc, PhD, Vice President Global Business, Roche Molecular Systems
                              Mark Ratain, MD, Leon O. Jacobson Professor of Medicine, Chairman, Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago
                              Randy Scott, Executive Chairman, Genomic Health
                              Elizabeth Mansfield, PhD, Senior Genomics Advisor, Office of FDA Chief Scientist, FDA 
                              Felix W. Frueh, PhD, Vice President, R&D - Personalized Medicine, Medco Health Solutions, Inc.
                              Bruce Quinn, MD, Senior Health Policy Specialist, Foley Hoag, LLP

5:30 - 7:00            Networking Reception

 7:00 - 9:30            Fifth Annual Albert Szent-Gyorgyi Prize Award Dinner 

Wednesday, March 17

7:15 – 8:00 am       Continental Breakfast

8:00 - 8:30               Opening Remarks, Conference Overview
                                Mark Simon, President, Williver Group LLC, Wednesday Moderator

8:30 – 9:00              The Challenge of Targeting EGFR: Lessons Learnt and Future Directions With Gefitinib  
   Alison A. Armour, MD, Iressa Medical Science Director, AstraZeneca ,UK  

9:00 – 9:30              Market Access Under Healthcare Reform
                                Lee Blansett, Senior Vice President, Kantar Health

9:30 – 10:00            Novel Antiandrogens for Prostate Cancer
                                Charles Sawyers, MD, Chairman, Memorial Sloan-Kettering Cancer Center Human Oncology and Pathogenesis Program

10:00 - 10:30           Networking Break

10:30 – 11:00           Keynote Presentation: Taking the Cellulite Out of Cancer
                                 Daniel D. Von Hoff, MD, Physician-in-Chief, Director, Translational Research, TGen, Clinical Professor of Medicine, University of Arizona

11:00 – 11:30           New Institutional and Technical Approaches to Tackle the Cancer Problem
                                 Robert G. Urban, PhD, Executive Director, David H. Koch Institute for Integrative Cancer Research, MIT

11:30 - 12:00            Merck-AstraZeneca - A New Paradigm in Drug Development
                                  Pearl Huang, PhD, Vice President, Franchise Integrator, Oncology, Merck  

12:00 – 1:15             Luncheon

1:15 – 2:30              Panel Discussion: Adaptive Trial Design
                                 Eric Rubin, MD, VP Oncology Clinical Research, Merck
                                 Mark Ratain, MD, Leon O. Jacobson Professor of Medicine, Chairman, Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago
                                 Donald Berry, PhD, Chairman, Department of Biostatistics and Frank T. McGraw Memorial Chair of Cancer Research, MD Anderson Cancer Center
                                 Roy S. Herbst, MD, PhD, Professor of Medicine, Department of Thoracic Head and Neck Cancer, Division of Cancer Medicine, MD Anderson Cancer Center

  2:30 – 3:30             Panel Discussion: New Imaging Strategies Beyond RESIST
                                 David Geho, MD, PhD, Clinical Project Leader, General Electric Corporation
                                  Lawrence H. Schwartz, MD, James Picker Professor & Chairman, Department of Radiology, New York Columbia-Presbyterian Medical Center
                                 Nola Hylton, PhD, Professor of Radiology, Director, MRI Research Program, UCSF
                                 Wendy Hayes, DO, Imaging Director, Discovery Medicine and Clinical Pharmacology, Bristol-Myers Squibb
                                 Gary Kelloff, MD, Special Advisor, Division of Cancer Treatment & Diagnosis, NCI, NIH

3:30                         Conference Concludes

Conference Slides (participants only)            Description               Sponsors